DDInter518 DDInter1376
Dexfenfluramine, also marketed under the name Redux, is a serotoninergic anorectic drug. For a fairly limited time during the middle of the nineties, the US FDA had approved it for use in managing weight loss. However, following multiple concerns about the cardiovascular side-effects of the drug, such approval was withdrawn.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Dexfenfluramine {u} may lead to a major life threatening interaction when taken with {v} Metamfetamine
Dexfenfluramine {u} (Compound) resembles {v} (Compound) Fenproporex
Dexfenfluramine {u} (Compound) binds {v} (Gene) SLC6A4
Dexfenfluramine {u} (Compound) upregulates {v} (Gene) ARL4C
Dexfenfluramine {u} (Compound) downregulates {v} (Gene) TIMM9
Dexfenfluramine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Tolterodine
Dexfenfluramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dacomitinib
Dexfenfluramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pioglitazone
Dexfenfluramine {u} may lead to a major life threatening interaction when taken with {v} Sibutramine
Dexfenfluramine may lead to a major life threatening interaction when taken with Metamfetamine
Dexfenfluramine (Compound) resembles Fenproporex (Compound)
Dexfenfluramine (Compound) binds SLC6A4 (Gene)
Dexfenfluramine (Compound) upregulates ARL4C (Gene)
Dexfenfluramine (Compound) downregulates TIMM9 (Gene)
Dexfenfluramine may cause a minor interaction that can limit clinical effects when taken with Tolterodine
Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Dacomitinib
Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Pioglitazone
Dexfenfluramine may lead to a major life threatening interaction when taken with Sibutramine